10-year follow-up of intensive glucose control in type 2 diabetes.

By Rury R. Holman, S. Paul, M. A. Bethel, D. Matthews, H. Andrew, W. Neil. New England Journal of Medicine, 2008

6,946 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/796f87021518c0bff851ff1ade5f780e3569e4ae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Molecular Biology

Citations in the corpus

Diabetes in Sub Saharan Africa 1999-2011: Epidemiology and public health implications. a systematic review (2011, background): “Assessing the public health importance of diabetes demands an appreciation of the impact of diabetes on other diseases and population mortality, and in particular the benefits of well-controlled diabetes for averting costly cardiovascular and microvascular complications [7,94].”
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise (2010, background): “This is exemplified by the treatment-limiting side effects of many available antidiabetic agents, particularly in patients with a longer duration of disease (2-5).”
International Consensus on Use of Continuous Glucose Monitoring (2017, methodology): “• Self-monitoring of blood glucose (SMBG) has been shown to be helpful or to correlate with effective management in insulin-treated and non-insulin-treated diabetes (1-4, 21, 22) [C,C,C,C,A,C], however, SMBG has notable limitations.”
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, neutral): “Most patients in the UKPDS were followed for a further 10 years of post-trial observational monitoring.(444) No attempt was made to maintain previously assigned therapies and the glycaemic control in the two groups rapidly converged.”
The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation (2020, background): “For instance, the Diabetes Control and Complications Trial in patients with T1D and the United Kingdom Prospective Diabetes Study in patients with T2D demonstrated that patients on the conventional treatment who did not achieve adequate blood glucose control were at higher risk of vascular complicat”
Glucose Biosensors: An Overview of Use in Clinical Practice (2010, background): “The findings of the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) clearly showed that intensive control of elevated levels of blood glucose in patients with diabetes, decreases the frequency of complications such as nephropathy, neuropathy,”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 (2019, background): “may reduce risk of cardiovascular events and death (35).”
6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. (2021, background): “33% with metformin as initial pharmacotherapy) and in all-cause mortality (13% and 27%, respectively) (33).”